The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 4, 2009, Pages 815-820

  Smirnova, Maria V ^a   Vostrov, Sergey N ^a   Strukova, Elena V ^a   Dovzhenko, Svetlana A ^a   Kobrin, Michael B ^a   Portnoy, Yury A ^a   Zinner, Stephen H ^b   Firsov, Alexander A ^a  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b MOUNT AUBURN HOSPITAL   (United States)

Author keywords

In vitro studies; Methodology; Selection of resistant staphylococci

Indexed keywords

DAPTOMYCIN; GARENOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; SELECTION, GENETIC; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 70349443130     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp287     Document Type: Article

References (15)

1. Firsov AA, Zinner SH, Lubenko IY. In vitro dynamic models as tools to predict antibiotic pharmacodynamics In: Nightingale CH, Ambrose PG, Drusano GL et al., eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. 2nd edn. New York: Informa Healthcare USA, Inc., 2007; 45-78.
2. Firsov AA, Vostrov SN, Lubenko IY et al. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 1604-13.
3. Firsov AA, Vostrov SV, Lubenko IY et al. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother 2004; 54: 178-86.
4. Tam VH, Louie A, Deziel MR et al. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: A new paradigm for optimizing pharmacodynamics to counter select resistance. Antimicrob Agents Chemother 2007; 51: 744-47.
5. Zinner SH, Lubenko IY, Gilbert D et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: Related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 2003; 52: 616-22.
6. Firsov AA, Smirnova MV, Lubenko IY et al. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 2006; 58: 1185-92.
7. MacGowan AP, Rogers CA, Holt HA et al. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2003; 47: 1088-95.
8. Tam VH, Louie A, Fritsche TR et al. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis 2007; 195: 1818-27.
9. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001; 33 Suppl 3: S147-56.
10. 2+ and albumin on these drugs. Antimicrob Agents Chemother 1991; 35: 1710-6.
11. Dvorchik BH, Brazier D, DeBruin MF et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-23.
12. Woodworth JR, Nyhart EH, Brier GL Jr et al. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992; 36: 318-25.
13. Firsov AA, Vostrov SN, Shevchenko AA et al. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: Action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother 1997; 41: 1281-7.
14. Firsov AA, Lubenko IY, Smirnova MV et al. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: Oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob Agents Chemother 2008; 52: 1924-8.
15. Firsov AA, Smirnova MV, Strukova EN et al. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: Bolus versus continuous infusion. Int J Antimicrob Agents 2008, 32: 488-93.